CN Social Media Links

Patients with SCLC who received ociperlimab and tislelizumab plus cCRT achieved a median PFS of 12.6 months compared with 9.5 months with cCRT alone.

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

The primary end point of PFS was not statistically significant with sacituzumab govitecan vs chemotherapy as first-line treatment in HR+/HER2– metastatic breast cancer.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Giredestrant’s safety in the lidERA BC trial was consistent with its known profile, with a lower discontinuation rate vs SOC endocrine therapy.

Data from the phase 1b MonumenTAL-2 study support continued investigation of talquetamab/pomalidomide in the phase 3 MonumenTAL-6 trial.